I think we need to think about priorities.
It's got great bipartisan support. It's being held up a little bit, but it's going to pass.
The fact that we were using 60-year-old technologies to make important vaccines like H1N1 was one of the reasons that Se...
I just think we're relying too much on the FDA.
Now, that's a good idea. I like that.
Future attacks remain a very real threat. Yet, we are still using the same anthrax vaccine that was developed 40 years a...
I don't understand how this fund--the Strategic Investor Fund----would work different from BARDA.
I'm concerned, because this subcommittee put a lot of money--$15 billion through this subcommittee, since fiscal year 20...
We have to sort of think about what are the priority areas, knowing full well that we can't guarantee absolute, 100-perc...
Funding provided by this subcommittee is what pays for the Nation's medical countermeasures (MCM), including the drugs, ...
Thank you again, Dr. Pavia.
For all that we put on their plate.
I'm just thinking out loud here--is it FDA, or do we need to take something out of the FDA?
I think the plan is a good plan, from what I've been able to read about it and to take a look at it.
And thank all of you for your testimonies, and for your work in this field, and your leadership in this field.
BARDA would be the purchaser, but this fund would be the investor.
I think now's time to take stock and think, on the reauthorization, do we need to do some realignment here?
We know flu is here... we know there are a lot of other strains of flu out there.
